Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CytoDyn Inc.

< Previous 1 2 Next >
CytoDyn Announces FDA Has Lifted Clinical Hold
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Webcast to Provide Company Update
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
November 2023 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Company Updates and Investment Community Update Webcast
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces President Takes Medical Leave of Absence
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn to Hold Webcast to Provide a Company Update
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Appointment of Additional Directors with Industry Experience
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.